

Human PD-L1 / B7-H1 / CD274 Protein (ECD, Fc Tag)

Catalog Number: 10084-H05H



Sino Biological
Biological Solution Specialist

General Information

Gene Name Synonym:

B7-H; B7-H1; B7H1; PD-L1; PDCD1L1; PDCD1LG1; PDL1

Protein Construction:

A DNA sequence encoding the human CD274 (NP_054862.1) (Met1-Thr239) was expressed with the Fc region of mouse IgG1 at the C-terminus.

Source: Human

Expression Host: HEK293 Cells

QC Testing

Purity: > 95 % as determined by SDS-PAGE.

Bio Activity:

Measured by its binding ability in a functional ELISA. Immobilized recombinant Human PD1-His (Cat:10377-H08H) at 10 µg/ml (100 µl/well) can bind human PD-L1 (Cat:10084-H05H) with a linear range of 1.28-20 µg/ml.

Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocytes. The ED₅₀ for this effect is typically 0.4-3 µg/ml.

Endotoxin:

< 1.0 EU per µg protein as determined by the LAL method.

Stability:

Samples are stable for up to twelve months from date of receipt at -70 °C

Predicted N terminal: Phe 19

Molecular Mass:

The recombinant human CD274 consists of 455 amino acids and predicts a molecular mass of 51.7 kDa.

Formulation:

Lyophilized from 20 mM Tris, 150 mM NaCl, 10 % Glycerol, pH 8.5.

Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

Usage Guide

Storage:


Store it under sterile conditions at -20°C to -80°C upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

Avoid repeated freeze-thaw cycles.

Reconstitution:

Detailed reconstitution instructions are sent along with the products.

SDS-PAGE:



Protein Description

Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1 (PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

References

1. Iwai Y, *et al.* (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. *Proc Natl Acad Sci U S A.* 99(19): 12293-7. 2. Ghebeh H, *et al.* (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. *Neoplasia.* 8(3): 190-8. 3. Salih HR, *et al.* (2006) The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. *Exp Hematol.* 34(7): 888-94.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Tel: +86-400-890-9989 (Global), +1-215-583-7898 (USA), +49(0)6196 9678656 (Europe)

Website: <http://www.sinobiological.com>